Hyperthermic Intrathoracic Chemotherapy (HITHOC) in India

Hyperthermic Intrathoracic Chemotherapy, commonly called HITHOC or HITOC, is a specialised procedure used in selected patients with cancer involving the pleura, the thin lining around the lungs. It combines surgery to remove visible tumour deposits with circulation of heated chemotherapy medicine inside the chest cavity. The aim is to treat microscopic cancer cells that may remain on pleural surfaces after surgical removal.

For international patients considering HITHOC in India, the decision requires careful review of the cancer type, its extent, previous treatment and overall fitness for major thoracic surgery. MedTripz helps patients from the Middle East, Africa and CIS understand their options, obtain medical opinions and coordinate the practical arrangements for treatment. The treating oncology team determines whether this approach is appropriate.

What Is Hyperthermic Intrathoracic Chemotherapy?

HITHOC is a form of regional chemotherapy delivered directly into the pleural cavity during an operation. After the surgeon removes as much visible tumour as considered safely possible, a specialised perfusion system circulates a heated chemotherapy solution through the chest cavity for a controlled period.

The combination of local drug delivery and heat is intended to increase the effect of chemotherapy on residual tumour cells along the pleural surface. Because the medicine is delivered into a defined body cavity rather than being given only through a vein, exposure is concentrated in the treated area. However, some medicine can enter the bloodstream, and HITHOC does not eliminate the possibility of systemic side effects.

HITHOC is different from HIPEC. HITHOC treats the pleural cavity in the chest, whereas HIPEC is used in selected conditions involving the abdominal cavity. The two procedures are not interchangeable.

Which Cancers May Be Considered for HITHOC?

HITHOC may be discussed as part of a multimodal treatment plan for carefully selected patients with malignancy affecting the pleura. Clinical experience and published studies most often describe its use in:

• Malignant pleural mesothelioma.

• Pleural spread from thymoma or thymic carcinoma.

• Selected secondary pleural metastases from cancers that began in another organ.

The suitability of HITHOC depends on more than the cancer diagnosis. Specialists assess whether the disease is mainly confined to one side of the chest, whether visible deposits can be surgically removed to a meaningful extent, whether the original cancer is controlled where relevant, and whether the patient can tolerate a major operation.

HITHOC is not a routine option for every person with pleural cancer or pleural fluid. Evidence, patient-selection criteria and treatment protocols continue to develop. The expected benefit must be discussed against established alternatives and the risks of surgery.

Who May Be a Candidate?

A multidisciplinary team generally reviews the case before recommending this procedure. The assessment may include:

• Cancer pathology: Review of biopsy or surgical specimens to confirm the diagnosis and tumour characteristics.

• Disease staging: Contrast-enhanced chest CT and, where appropriate, PET-CT or other imaging to understand pleural involvement and check for disease outside the chest.

• Operability: Assessment of whether the visible disease can be removed safely and what extent of pleural or adjacent tissue surgery may be required.

• Lung and heart function: Pulmonary function tests and cardiac evaluation help estimate the ability to tolerate anaesthesia and thoracic surgery.

• Kidney function and blood tests: These are important because some chemotherapy agents used during perfusion, particularly cisplatin-based regimens, can affect the kidneys and blood counts.

• General fitness: Nutrition, performance status, other medical conditions, current medicines and previous cancer treatments are considered.

Significant kidney impairment, poor cardiopulmonary reserve, extensive disease outside the chest or inability to undergo major surgery may make HITHOC unsuitable. These are examples of factors for specialist assessment, not a substitute for an individual decision.

How Is the HITHOC Procedure Performed?

HITHOC is usually performed in the operating theatre under general anaesthesia and is commonly combined with cytoreductive surgery in the same session.

1. Surgical Removal of Visible Tumour

The thoracic surgeon accesses the chest and removes visible tumour deposits from the pleural surfaces. Depending on disease distribution, the operation may involve pleurectomy and decortication or another carefully selected resection. The precise surgical approach depends on tumour location, lung involvement and the aim of achieving the safest possible removal. The extent of surgery can vary considerably between patients.

2. Placement of Perfusion Tubes

After the surgical phase, inflow and outflow tubes are positioned in the chest cavity. These connect to a specialised external perfusion machine. The team checks the circuit and monitors fluid movement and temperature to support even distribution of the solution.

3. Circulation of Heated Chemotherapy

A chemotherapy solution, often based on cisplatin in published protocols, is warmed and circulated through the pleural cavity. Research reports commonly describe temperatures around 40–43°C and perfusion periods of approximately 60 minutes, although protocols differ by centre, drug selection and patient factors. The surgical and anaesthesia teams continuously monitor temperature, circulation and other vital parameters.

4. Completion and Monitoring

At the end of perfusion, the solution is drained and the chest is managed according to the surgical plan. Chest drains may remain temporarily to remove air or fluid and support lung re-expansion. The patient is transferred to a closely monitored recovery area, and in some cases intensive care is required.

Hyperthermic Intrathoracic Chemotherapy Cost in India

The Hyperthermic Intrathoracic Chemotherapy Cost in India depends on the complexity of the operation and the patient's clinical requirements. MedTripz currently lists the following indicative figures for this procedure:

These figures are reference estimates, not a confirmed quotation or a guarantee of the final bill. The Hyperthermic Intrathoracic Chemotherapy Cost in India for international patients may vary according to the extent of tumour removal, surgical technique, chemotherapy medicines, investigations, intensive-care requirements, length of admission and management of complications.

Before travelling, patients should request a written, itemised estimate that clarifies what is included. Ask whether it covers surgeon and anaesthesia fees, operating theatre charges, perfusion equipment and medicines, pathology, imaging, hospital accommodation, intensive care, blood products and follow-up. Additional procedures or an extended stay may increase the total cost.

MedTripz can help coordinate medical records and request a treatment estimate from the relevant provider. The final plan and charges are confirmed by the treating facility after clinical review.

Potential Benefits and Important Limitations

The main rationale for HITHOC is to expose the pleural surfaces to heated chemotherapy after visible tumour has been removed. This may help address microscopic disease that cannot be seen or safely removed during surgery. Local delivery can also create a higher concentration of medicine in the treated cavity than would be achieved by relying on blood circulation alone.

However, HITHOC should not be described as a cure or as proven to prevent recurrence in every patient. Published research is encouraging in selected groups, but studies are relatively limited and techniques vary. Current evidence does not establish one standard protocol or a definitive benefit for every pleural cancer. A specialist should explain the evidence relevant to the patient's diagnosis and discuss alternatives, which may include systemic therapy, other surgery, radiation or symptom-focused care.

Risks and Possible Complications

HITHOC combines major chest surgery, anaesthesia and chemotherapy, so complications can arise from any part of the treatment. Possible risks include:

• Bleeding, infection, wound problems or blood clots.

• Air leak, pneumonia, breathing difficulty or fluid accumulation around the lung.

• Pain, fatigue, nausea and vomiting.

• Changes in kidney function, electrolyte levels or blood counts.

• Heart or circulation-related complications.

• Reactions or toxicity associated with the chemotherapy medicine.

The likelihood and severity of these problems depend on the patient's health, the extent of surgery and the medicines used. The team monitors kidney function, blood results, fluid balance, breathing and pain during recovery. Patients should ask the surgeon and oncologist which risks are most relevant to their case and what measures are planned to reduce them.

Recovery After HITHOC

Recovery varies because the surgical component may be extensive. MedTripz lists an indicative hospital stay of 8–10 days, but this is not a fixed timeline. Some patients may need a longer admission depending on lung recovery, chest-drain output, pain control, mobility and any complications.

After discharge, recovery continues at home or in suitable accommodation. The treating team may recommend breathing exercises, gradual walking, wound care, pain medicines, nutrition support and restrictions on strenuous activity. Follow-up appointments and imaging are arranged according to the cancer type and individual treatment plan. Further systemic treatment may be considered when clinically appropriate.

International patients should not plan an immediate return flight after discharge without medical clearance. The treating team should confirm that the patient is stable for travel, advise on flight timing and explain how follow-up will be coordinated after returning home.

Why Consider India for HITHOC?

India is a destination considered by international patients seeking specialised cancer care and complex surgical treatment. Patients may be able to compare treatment plans and estimated costs while accessing multidisciplinary evaluation involving thoracic surgery, surgical oncology, medical oncology, anaesthesia, radiology, pathology and critical care.

The quality of care should be assessed provider by provider rather than assumed from the destination alone. Before choosing a centre, patients can ask about its experience with pleural malignancies and HITHOC, the number and type of cases managed, the proposed surgical approach, intensive-care facilities, chemotherapy safety protocols, expected recovery and arrangements for complications and follow-up.

A clear written treatment plan, transparent estimate and direct discussion with the treating specialists are important parts of an informed decision.